Stock Analysis of Keros Therapeutics Inc (KROS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code KROS
Close 46.87
Change 0.560 / 1.21 %
Volume 405420
Vol Change 168163 / 70.88 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Keros Therapeutics Inc
PE (TTM)

-2175.29

Very Poor
Price / Book

988.81

Very Poor
Price / Sales

1490182

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

1691.25 M

Enterprise Value

1361.11 M

ROA (TTM)

-41.68

Very Poor
ROE (TTM)

-45.46

Very Poor
Net Margin (TTM)

-68505.13

Very Poor
Revenue

99.25 %

151000
Net Profit

46.15 %

-152992.00 K
Debt to Equity

0.0030

Excellent
Altman Z Score

25.08

Excellent
Quick Ratio

13.67

Excellent
Cash Ratio

13.59

Excellent


Highs/Lows of Keros Therapeutics Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week48.48 3.32 % 0.513 % 49.2745.3428-May-2431-May-24
Two Week52.28 10.35 % 0.486 % 52.94545.3420-May-2431-May-24
One Month56.39 16.88 % 4.80 % 62.1945.3403-May-2431-May-24
Three Month67.5 30.56 % 3.56 % 71.2945.3408-Mar-2431-May-24
Six Months30.34 54.48 % 15.54 % 73.027.3129-Feb-2412-Dec-23
One year47.86 2.07 % 26.26 % 73.027.0329-Feb-2426-Oct-23
Two year33.8 38.67 % 27.72 % 73.027.0329-Feb-2426-Oct-23


Technical View of Keros Therapeutics Inc
RSI

29.84

Mild Bullish
MACD

-3.10

Bearish
ADX

39.06

Bearish
Super Trend

53.34

Mild Bearish
Williams %R

-84.99

Mild Bullish
CCI

-119.62

Mild Bullish


EMA 5

47.56

Mild Bearish
EMA 15

50.53

Mild Bearish
EMA 50

55.32

Strong Bearish
EMA 100

54.53

Bearish
SMA 100

58.71

Strong Bearish
SMA 200

45.95

Bullish
SMA 5 / 20

47.43 / 52.86

Strong Bearish
SMA 15 / 50

50.80 / 57.69

Strong Bearish
SMA 50 / 200

57.69 / 45.95

Bullish




Charts of Keros Therapeutics Inc


Returns of Keros Therapeutics Inc with Peers
Period / StockKROSZLABNEONAMS
1 Week-3.32%-0.781%-3.72%-0.372%
1 Mth-16.88%12.53%-1.51%-14.03%
3 Mth-30.56%-15.25%-12.12%-17.91%
6mth54.48%-34.85%-24.55%92.11%
1 Year-2.07%-45.28%-20.20%35.28%
2 Year38.67%-38.90%62.83%90.16%
5 Years--32.16%-36.85%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Keros Therapeutics Inc with Peers
Ratio / StockKROSZLABNEONAMS
PE-2175.29-12679.54-20.47-15.43
P/B988.814914.091.8210.90
ROA-41.68-31.71-5.01-58.98
ROE-45.46-38.76-8.88-70.67
Debt To Equity0.00300.00890.5780.0002
Revenue151000
99.25 % 		263490 K
22.53 % 		591643 K
16.07 % 		14090.00 K
85.55 %
Net Income-152992.00 K
46.15 % 		-300960.00 K
32.11 % 		-87968.00 K
39.02 % 		-176937.00 K
126.69 %


Technicals of Keros Therapeutics Inc with Peers
Technical / StockKROSZLABNEONAMS-
ADX39.0622.9216.2226.74
CMF-0.181-0.103-0.0497-0.211
MFI6.2052.4530.8634.31
RSI29.8446.9239.0437.22
MACD Abv SignalFalseFalseFalseFalse
Price Above 50 MAFalseTrueFalseFalse-
Price Above 200 MATrueFalseFalseTrue-


About : Keros Therapeutics Inc

Address : 1050 Waltham Street, Lexington, MA, United States, 02421
Tel : 617 314 6297
URL : https://www.kerostx.com
Code : KROS, ISIN : US4923271013, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 08_Apr_2020
Employee Count : 141

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)